Merck and Moderna’s decade-long 50/50 collaboration on intismeran autogene has delivered a landmark Phase 3 melanoma success in August 2026, driving Moderna’s market value sharply higher while reinforcing the existing partnership structure without necessitating a full merger. Merck has pursued separate M&A activity, including the $6.7 billion Terns Pharmaceuticals deal and other oncology and cardiopulmonary acquisitions, to diversify ahead of Keytruda’s patent cliff. Moderna is independently expanding manufacturing capacity and oncology infrastructure. With the 2026 implied probability of an announced transaction at just 8.5%, realistic challenges to the consensus would require unexpected regulatory setbacks, acute capital needs at either firm, or a strategic pivot that overrides the current profitable alliance.